Proactive Investors
13 Jul 2026, 06:42 UTC · 2h ago
IXICO guidance unchanged after Huntington's cancellations
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Proactive Investors
13 Jul 2026, 06:42 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
IXICO PLC confirmed that its upgraded revenue guidance for the 2026 and 2027 financial years remains unchanged. — Maintaining upgraded guidance despite client losses signals management confidence and operational resilience.
+0.40Two clients discontinued Huntington's disease programmes, reducing IXICO's contracted order book by approximately £1.5 million over the next two financial years. — Direct loss of contracted revenue is a negative fundamental development, though partially offset by overall order book growth.
-0.30IXICO's current order book remains 21% higher than the level reported at the end of the 2025 financial year. — Net growth in the order book suggests strong demand for the company's AI platform despite individual project cancellations.
+0.20Continue reading
6 related stories
Top 1 mover · tap to explore
Coiled Therapeutics is introducing a new softgel formulation for its lead cancer drug candidate AO-252 to improve absorption. — Iterative drug formulation improvements are standard but positive steps toward clinical success.
+0.10Which stocks this story touches
Positive progress on lead drug candidate AO-252 with first patient dosing expected this month.
Despite losing £1.5 million in contracts, the company maintained revenue guidance and reports an order book 21% above the previous year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
